Rhythm Pharmaceuticals reports Q1 EPS (83c), consensus (86c)

Reports Q1 revenue $60.11M, consensus $56.07M. “The U.S and European approvals of IMCIVREE mark a transformational milestone for patients with acquired hypothalamic obesity who, until now, had no approved therapies for this devastating disease,” said David Meeker, Chairman, Chief Executive Officer and President of Rhythm Pharmaceuticals (RYTM). “The U.S. launch is off to a strong start, as patient demand and physician engagement in this early stage of the launch reinforce the significant unmet need and long-term opportunity in acquired HO. With European Commission authorization for acquired HO earlier than expected, we look forward to engaging with country-level officials with launches anticipated in 2027. We are progressing rapidly in Japan for acquired HO, as well; regulatory review is underway, and if approved, we anticipate launching there in the second half of 2026.”